Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Investigates Tenure Of FDA Medical Products Office Acting Head

This article was originally published in The Tan Sheet

Executive Summary

In a letter to FDA Commissioner Hamburg, Energy and Commerce Committee leaders say public information discrepancies raised questions about Leona Brenner-Gati’s status and “the circumstances surrounding her resignation.”

You may also be interested in...



FDA Mines Small Field Of Industry Candidates To Fill Executive Vacancies

Criteria for FDA’s leadership posts are extensive and the hiring process is long, but Richard Moscicki still believes industry and academics should consider applying. As more long-time officials retire, he says it is critical to fill open positions to allow for a “smooth transition over an extended period of time.”

FDA Mines Small Field Of Industry Candidates To Fill Executive Vacancies

Criteria for FDA’s leadership posts are extensive and the hiring process is long, but Richard Moscicki still believes industry and academics should consider applying. As more long-time officials retire, he says it is critical to fill open positions to allow for a “smooth transition over an extended period of time.”

FDA Mulls Another Makeover; Looking To Integrate Agency Functions

FDA Commissioner Hamburg has appointed 10 officials to come up with a plan to realign the agency, with the goal of moving toward a “specialized program-based model.”

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel